Acurable, a UK-based medical device company, announced that it has raised €11 million ($10.8 million) in a Series A funding round led by Kibo Ventures.
Mundi Ventures, Comprador Holdings and Kindred Capital participated in the raise.
The company will use the funds to accelerate international expansion of its first home sleep testing device, the AcuPebble SA100, which enables users to detect and monitor obstructive sleep apnea.
Acurable will also develop new products for chronic obstructive pulmonary disease (COPD), asthma and cardiovascular disease.
The AcuPebble SA100 launched in the UK and Spain in 2021. The company is looking to expand in both countries and expand in Europe and North America.
The device has received CE marking in Europe for the automated diagnosis of OSAS at home. Last year he received FDA 510(k) clearance in the United States to detect, record and interpret physiological signals, such as a patient’s breathing pattern, during sleep to pre-screen for OSAS.
Several companies offer home sleep apnea diagnostic tests, including the Israeli company Itamar Medicalwhich expanded the capabilities of its home sleep apnea diagnostic test line in 2021.
Its WatchPAT system attaches to the user’s index finger, chest, and wrist, measuring and recording peripheral arterial signal (PAT), heart rate, oximetry, actigraphy, body position, snoring and chest movements to identify sleep apnea events.
In 2021, it expanded its capabilities with SleePath, allowing users to document subjective data from its test directly in the connected app, providing physicians with a more complete picture via self-reports and sleep study metrics.
In 2020, ResApp launched SleepCheck, an at-home sleep apnea screening app, and that same year a French company Withing launched Sleep Analyzer, an under-mattress sleep tracking mat that can be used to detect sleep apnea.